| Registry | NCT00042679 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional; non randomized, single group, masking: none, treatment |
| Sponsor | Eli Lilly and Company (Industry) |
| Conditions | Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung |
| Interventions | Gemcitabine, Carboplatin, LY900003 (Drug) |
| Dates | start 2002-06-01, first posted 2002-08-06, last updated 2006-07-19 |
| Locations | 11 sites in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Carcinoma, Non-Small-Cell Lung All trials for Pulmonary Neoplasms All trials of Gemcitabine All trials of Carboplatin
The purposes of this study are to determine the following:
Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long.
If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer.
The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs.
How LY900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine.
Whether LY900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.
Definition: The phase 2 study will provide important information regarding effects of LY900003 on safety and efficacy of patients treated with gemcitabine and carboplatin. LY900003 will be given at approximately 2 mg/kg/day for the first 14 days of a 21-day cycle. The dose and schedule for LY900003 administration are based on results of prior studies of LY900003 and are currently being used in other studies of LY900003. Gemcitabine will be administered on Days 1 and 8 at 1250 mg/m2 and carboplatin will be given on Day 1 at AUC 5.
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Diagnosis of Non-Small-Cell Lung Cancer. * Stage IV or Stage IIIB disease. * ECOG Performance Status of 0 or 1. * Adequate organ function * One unidimensionally measurable lesion. Exclusion Criteria: * Prior therapy for NSCLC. * Serious concomitant disorders. * Untreated CNS metastases. * Uncontrolled, active infection. * Previous LY900003/ISIS trial participation.
| Facility | City | Country | Status |
|---|---|---|---|
| Bakersfield, California | United States | ||
| Berkeley, California | United States | ||
| Torrance, California | United States | ||
| Miami Beach, Florida | United States | ||
| Chicago, Illinois | United States | ||
| Park Ridge, Illinois | United States | ||
| Baltimore, Maryland | United States | ||
| Chattanooga, Tennessee | United States | ||
| Lubbock, Texas | United States | ||
| Charlottesville, Virginia | United States | ||
| Milwaukee, Wisconsin | United States |